Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating PF-07248144 in combination with Fulvestrant for HR-positive, HER2-negative advanced or metastatic breast cancer after prior th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• PF-07248144 (PF-07248144)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING